FDA issues CRL to Cumberland Pharma for Acetadote sNDA
In its CRL, the agency confirmed that patients with Coma Grade I/II observed a numerically higher rate of transplant-free survival, but also noted that there was not sufficient
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.